Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia

被引：0

作者：

Tedeschi, Alessandra ^{[1
]}

Rossi, Davide ^{[2
]}

Coscia, Marta ^{[3
]}

Vismara, Eleonora ^{[1
]}

Petrizzi, Valeria Belsito ^{[4
]}

Orlandi, Ester ^{[5
]}

Cascavilla, Nicola ^{[6
]}

Scarfo, Lydia ^{[7
]}

Motta, Marina ^{[8
]}

Vitale, Candida ^{[3
]}

Ricci, Francesca ^{[1
]}

De Paoli, Lorenzo ^{[2
]}

D'Arco, Alfonso Maria ^{[4
]}

Gallamini, Andrea ^{[9
]}

Gaidano, Gianluca ^{[10
]}

Morra, Enrica ^{[1
]}

Massaia, Massimo ^{[3
]}

Montillo, Marco ^{[1
]}

机构：

[1] Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy

[2] Amedeo Avogadro Univ, Dept Hematol, Novara, Italy

[3] Univ Turin, Dept Med & Expt Oncol, Sect Hematol, Turin, Italy

[4] Nocera Inferiore Hosp, Dept Internal Med, Nocera Inferiore, Italy

[5] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy

[6] IRCCS, Dept Hematol, San Giovanni Rotondo, Italy

[7] Ist Sci San Raffaele, Lymphoma Unit, Dept Oncohematol, Milan, Italy

[8] Brescia Hosp, Spedali Civili, Dept Hematol, Brescia, Italy

[9] Santa Croce Hosp, Dept Hematol, Cuneo, Italy

[10] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.2898.2898

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2898

引用

页数：2

共 50 条

[41] COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Casado, L. F.
Hernandez, J. A.
Jarque, I
Echave, M.
Casado, M. A.
Castro-Gomez, A.
VALUE IN HEALTH, 2017, 20 (09) : A557 - A557
[42] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Brown, J. R.
Eichhorst, B.
Hillmen, P.
Jurczak, W.
Kazmierczak, M.
Lamanna, N.
O'Brien, S. M.
Tam, C. S.
Qiu, L.
Zhou, K.
Simkovic, M.
Mayer, J.
Gillespie-Twardy, A.
Ferrajoli, A.
Ganly, P. S.
Weinkove, R.
Grosicki, S.
Mital, A.
Robak, T.
Osterborg, A.
Yimer, H. A.
Salmi, T.
Wang, M. -D. -Y.
Fu, L.
Li, J.
Wu, K.
Cohen, A.
Shadman, M.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04): : 319 - 332
[43] Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Shustik, C.
Bence-Bruckler, I.
Delage, R.
Owen, C. J.
Toze, C. L.
Coutre, S.
ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1185 - 1196
[44] Economic burden of relapsed/refractory chronic lymphocytic leukemia
Guerin, Annie
Ray, Saurabh
Gauthier, Genevieve
Hsu, Ling-I
Zhdanava, Maryia
Heroux, Julie
Wu, Eric
LEUKEMIA & LYMPHOMA, 2015, 56 : 40 - 41
[45] Update on the management of relapsed/refractory chronic lymphocytic leukemia
Bennett, Rory
Seymour, John F.
BLOOD CANCER JOURNAL, 2024, 14 (01)
[46] Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
C. Shustik
I. Bence-Bruckler
R. Delage
C. J. Owen
C. L. Toze
S. Coutre
Annals of Hematology, 2017, 96 : 1185 - 1196
[47] Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia
Maurer, Christian
Pflug, Natali
Bahlo, Jasmin
Kluth, Sandra
Rhein, Christina
Cramer, Paula
Gross-Ophoff, Carolin
Langerbeins, Petra
Fink, Anna-Maria
Eichhorst, Barbara
Kreuzer, Karl-Anton
Fischer, Norbert
Tausch, Eugen
Stilgenbauer, Stephan
Boettcher, Sebastian
Doehner, Hartmut
Kneba, Michael
Dreyling, Martin
Binder, Mascha
Hallek, Michael
Wendtner, Clemens-Martin
Bergmann, Manuela
Fischer, Kirsten
EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (03) : 253 - 260
[48] Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?
Robak, Tadeusz
LEUKEMIA & LYMPHOMA, 2023, 64 (05) : 907 - 909
[49] Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
Lesley J. Scott
Targeted Oncology, 2019, 14 : 493 - 504
[50] Update on the management of relapsed/refractory chronic lymphocytic leukemia
Rory Bennett
John F. Seymour
Blood Cancer Journal, 14

← 1 2 3 4 5 →